In a Notice to Hospitals, Canada’s national health regulatory agency, has warned about the use of laparoscopic morcellators during hysterectomies and surgeries for uterine fibroids. The notice warns that the use of a morcellator during minimally invasive hysterectomy or fibroid surgery may result in the spread and “upstaging” of an undetected uterine cancer. These cancers […]
In a Notice to Hospitals, Canada’s national health regulatory agency, has warned about the use of laparoscopic morcellators during hysterectomies and surgeries for uterine fibroids.
The notice warns that the use of a morcellator during minimally invasive hysterectomy or fibroid surgery may result in the spread and “upstaging” of an undetected uterine cancer. These cancers cannot “reliably” be detected preoperatively, according to Health Canada. The frequency of such unsuspected uterine cancer is estimated to be about 1-in-350, a higher rate than previously reported.
The power morcellator uses rapidly spinning blades to cut uterine tissue into small pieces that can be removed through tiny incisions. But when the woman has an undetected cancer, the morcellator can spread cancerous tissue in the patient’s abdomen, leading to a more aggressive cancer and diminishing the woman’s overall survival rate.
Health Canada is working with device manufacturers to revise the instructions for morcellator use. The agency is requesting that manufacturers include the following warnings in the labeling of electric morcellators:
Health Canada’s notice says the use of the device is contraindicated:
Health Canada says the risks and benefits of using tissue extraction bags to contain tissue released during laparoscopic electric morcellation procedures have not been determined.
The U.S. Food and Drug Administration (FDA) has recently issued similar warnings and labeling cautions, though the FDA stopped short of banning the device altogether.